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ABSTRACT: 
Intestinal dysbiosis is implicated in alcoholic hepatitis (AH). However, changes in the 
circulating microbiome, its association with the presence and severity of AH and its 
functional relevance in AH is unknown. Qualitative and quantitative assessment of 
changes in the circulating microbiome were performed by sequencing bacterial DNA in 
subjects with moderate (n=18) or severe AH (n=19).  These data were compared to 
heavy drinking controls (HDC) without obvious liver disease (n=19) and non-alcohol 
consuming controls (NAC, n=20). The data were related to endotoxin levels and 
markers of monocyte activation.  Linear Discriminant Analysis (LDA) Effect Size (LEfSe) 
analysis, inferred metagenomics and predictive functional analysis using PICRUSt were 
performed. There was a significant increase in 16S copies/ng DNA both in MAH 
(p<0.01) and SAH (p<0.001) subjects. Compared to NAC, the relative abundance of 
phylum Bacteroidetes was significantly decreased in HDC, MAH, and SAH (p<0.001). In 
contrast, all alcohol consuming groups had enrichment with Fusobacteria; this was 
greatest for HDC and decreased progressively in MAH and SAH.  Subjects with SAH 
had significantly higher endotoxemia (p=0.01). Compared to alcohol consuming groups, 
predictive functional metagenomics indicated an enrichment of bacteria with genes 
related to methanogenesis and denitrification.  Also, both HDC and SAH showed 
activation of type III secretion system which has been linked to gram negative bacterial 
virulence. Metagenomics in SAH vs NAC predicted increased isoprenoid synthesis via 
mevalonate and anthranilate degradation, known modulators of gram positive bacterial 
growth and biofilm production respectively. In conclusion, heavy alcohol consumption 
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appears to be the primary driver of changes in the circulating microbiome associated  
with a shift in its inferred metabolic functions. (263 words, word limit 275 words).  
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INTRODUCTION: 
Alcohol related liver disease remains a leading cause of morbidity and mortality 
in many parts of the world and has been linked to a decline in population survival in the 
United States (1-3). The spectrum of liver disease associated with consumption of 
alcohol in harmful amounts includes a fatty liver to steatohepatitis with varying degrees 
of fibrosis to cirrhosis (4). While many patients with alcoholic steatohepatitis remain 
relatively asymptomatic, some individuals develop jaundice and worsening liver function 
and present with the clinical syndrome of alcoholic hepatitis (AH), which was defined as 
previously described (5).   
AH is a serious form of alcohol-induced liver disease and is a common cause for 
liver-related hospitalization and mortality.  The risk of mortality is dependent on the 
severity of AH which is usually assessed by the Maddrey’s discriminant function or the 
model for end-stage liver disease (MELD) score (6). Severe AH (MELD > 20 or 
Maddrey’s DF > 32) is associated with a 20-30% mortality in 4-6 weeks and up to 40% 
within 6 months (7-9). Current therapies are only modestly effective in affected 
individuals (10) underscoring the need to develop more effective preventive and 
therapeutic strategies against AH.  This requires an in depth understanding of the 
pathogenesis of AH.  While much is now known about the mechanisms of disease 
development in AH (11, 12), there are still gaps in knowledge particularly related to why 
only some individuals at risk develop AH and what determines the severity of the 
disease. 
Recently, the role of the microbiome has gained attention as a contributor to the 
development of alcohol associated liver disease (13). Advances in molecular technology 
have now identified the presence of microbiota in the circulation of healthy humans by 
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sequencing 16S rDNA bacterial genes (14).  While many changes in the intestinal 
microbiome in those who consume large amounts of alcohol as well as those with 
alcohol-induced liver disease (including changes in intestinal fungi) have been 
described along with increased intestinal permeability, endotoxemia and activation of 
systemic inflammatory responses (15-19), there are no data on the circulating 
microbiome in patients with AH.  Changes in the blood microbiota and gut-microbiome 
based metagenomics signature have recently been linked to liver fibrosis in obese and 
nonalcoholic fatty liver disease (20, 21). 
As a first step in elucidating the potential role of the circulating microbiome in AH, 
we measured the circulating microbiome in those with moderate or severe AH and 
compared it to control individuals who consumed large amounts of alcohol but did not 
have clinical evidence of liver disease and another group of controls without liver 
disease who did not consume alcohol.  The specific aims of this study were to 
determine the qualitative and quantitative changes in the microbial populations and their 
associated metagenome in circulation with: (1) heavy alcohol consumption, (2) the 
presence of AH, (3) severe AH (SAH) versus moderate AH (MAH), heavy drinking 
controls (HDC) and non-alcohol controls (NAC).  We further related the changes in 
circulating microbiome to markers of monocyte activation and evaluated the 
interrelationship between circulating microbiome, markers of monocyte activation, and 
disease severity. We also evaluated the functional relevance of changes in the 
circulating microbiome using predictive functional metagenomics approach in this well-
characterized cohort of subjects who were recruited by the Translational Research and 
Evolving Alcoholic Hepatitis Treatment (TREAT) consortium. 
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MATERIALS AND METHODS 
This study was a collaborative effort between investigators from the TREAT 
consortium.  The TREAT consortium includes three clinical sites and a data 
coordinating center and enrolls subjects in either a prospective registry (NCT02172898) 
or in to specific clinical trials for AH. Subjects with well characterized AH (MAH and 
SAH) and controls (HDC and NAC) were studied in this analysis. All subjects provided 
informed consent for these analyses and the protocols were approved at each of the 
participating sites by their institutional review boards. The study was conceived, 
executed, analyzed and written up by the investigators who take full responsibility for 
the contents of this manuscript. 
Study cohort 
AH was defined by hyperbilirubinemia along with an elevated AST without 
alternate cause in an individual with a history of heavy alcohol consumption for at least 
6 months and with the last alcoholic beverage consumed within 6 weeks of 
presentation, as recently published (5). Where there was diagnostic uncertainty, a liver 
biopsy was performed if clinically indicated to confirm the diagnosis.  Those with a 
MELD score > 20 were considered to have severe AH (6) whereas those with lower 
values were classified as moderate AH.  These subjects were compared to those HDC 
subjects who had normal liver enzymes and bilirubin, and no clinical findings suggestive 
of alcoholic hepatitis.  The NAC group had no clinical, laboratory or imaging evidence of 
liver disease.  The exclusion criteria for this analysis included those with co-morbid 
alternate etiologies of liver disease such as hepatitis C etc., clinically overt and active 
infection (positive cultures, chest X-ray showing pneumonia).  
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Data collection and clinical evaluation 
Demographic, medical history and clinical data were collected. Alcohol drinking 
questionnaires to determine the quantity and pattern of alcohol consumption included 
the ten question Alcohol Use Disorders Identification Test (AUDIT), the Time Line 
Follow-Back (TLFB), as well as NIAAA alcohol drinking 6 question survey.  Blood 
samples were collected for complete blood counts, metabolic panel, hepatic panel, and 
coagulation tests.  The tests were performed at the local pathology and chemistry lab at 
each site. The MELD, Child-Turcotte-Pugh (CTP) Score and Maddrey’s Discriminant 
Function (DF) were also recorded and patients were managed as clinically indicated 
based on the standard of care at each clinical center. 
Circulating microbiome methodology (see supplementary material) 
Bioinformatics data processing and Statistical analysis 
Linear Discriminant Analysis Effect Size (LEfSe) analysis was performed on the 
OTU table using the online Galaxy interface to identify bacterial taxa that were 
differentially abundant in groups (22). Using the LEfSe algorithm, bacterial taxa that 
were differentially abundant in pairwise analysis for groups were first identified and 
tested using the Kruskal Wallis test with adjustments for multiple comparisons (p<0.05). 
Principal components analyses were also performed.  The identified features were then 
subjected to the linear discriminant analysis (LDA) model with a threshold logarithmic 
LDA score set at 2.0 and ranked. Respective cladograms were generated with genus at 
the lowest level. Quantitative plots of differential features were generated from genus 
level percent relative abundance data showing means with standard deviation using 
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GraphPad Prism 6 software. Specific correlations were performed using Spearman’s  
coefficient.  Venn diagrams were generated using the online tool jvenn (23).   
Inferred metagenomics and predicted functional analysis was initiated by  
generating closed reference sequence clustering OTU’s in QIIME (24). The quality- 
filtered, demultiplexed sequences were clustered by 97% similarity. Representative  
sequences were picked and aligned to the sequences from the Greengenes reference  
collection (gg_otus_13_5.tar.gz) to assign taxonomy.  
The resulting OTU table was used to generate inferred metagenome data using  
the online Galaxy interface for Phylogenetic Investigation of Communities by  
Reconstruction of Unobserved States (PICRUSt, version 1.0.0) with default settings as  
described (25). Briefly, the abundance values of each OTU were normalized to their  
respective predicted 16S rRNA copy numbers and then multiplied by the respective  
predicted gene counts for metagenome prediction. The resulting core output was a list  
of Kyoto Encyclopedia of Genes and Genomes (KEGG) orthologues and predicted gene  
count data for each sample. We used in house scripts to parse the output into KEGG  
module categories for functional pathways and structural complex hierarchies using the  
KEGG database (http://www.genome.jp/kegg/module.html). The output matrix  
containing the relative abundance of KEGG orthologous groups (KO) per sample was  
processed with the online Galaxy interface for LEfSe with a threshold logarithmic LDA  
score set at 2.0 and ranked. Respective cladograms were generated with modules at  
the lowest level. Quantitative plots of differential features were generated from  
normalized module level predicted gene data showing means with standard deviation.  
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Pathway KO differential enrichment images were generated using KEGG Mapper  
(v2.8)(26).  
RESULTS  
A total of 76 subjects (No alcohol controls, NAC=20, Heavy drinking controls,  
HDC=19, Moderate Alcoholic Hepatitis, MAH=18, Severe Alcoholic Hepatitis, SAH=19)  
were studied. The study groups were age and BMI comparable with male predominance  
among alcohol groups. The laboratory profile and severity of disease measures are  
described in Table 1. As expected, when compared with non-drinking controls and  
HDC, more pronounced anemia, leukocytosis, thrombocytopenia, abnormal hepatic  
panel, hyperbilirubinemia, hypoalbuminemia and coagulopathy were seen in subjects  
with AH. Similarly, the MELD score, Child Pugh score and discriminant function, all  
measures of disease severity, were highest in those with severe AH.  
  
Alcohol consumption and presence of AH is associated with Increased circulating  
bacterial DNA (Fig. 1a)  
Measurement of circulating 16S copies/ng DNA revealed a step wise increase  
from NAC to HDC to MAH to SAH (p< 0.01). Of note, compared to NAC, the mean 16S  
copies/ng DNA were significantly higher in both MAH (p<0.01) and SAH (p<0.001).  
These data demonstrate an increased circulating bacterial burden in subjects with  
moderate and severe alcoholic hepatitis.    
  
Impact of alcohol consumption and presence of AH on bacterial diversity and  
distribution of microbiota in circulation:  
Page 12 of 57
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 13 
 
  A detailed illustration of the relative abundance of bacteria at a phylum level for 
individual groups is shown in Fig. 1b.  The overall diversity of the microbiome, as 
assessed by the Shannon Diversity Index (27), was not significantly different across the 
four study groups (Fig. 1c). Further, when Principal Coordinate Analysis (PCoA) was 
performed to compare samples based on the Generalized UniFrac distance metrics with 
alpha value of 0.2 (Fig. 1d), no statistically significant differences were observed among 
the study groups. The relative bacterial abundance did however cluster separately (Fig. 
1e) and all alcohol-consuming groups had a statistically significant decrease in the 
relative abundance of the phylum Bacteroidetes (p< 0.0001, Fig 1f).    
 To further characterize the impact of alcohol consumption and presence of AH on 
the circulating microbiome, discriminative features cladograms (Fig. 2a) and abundance 
histograms (Fig 2b) based on an effect size cutoff of 2.0 for the logarithmic LDA score 
were plotted.  Compared to NACs, the circulating microbiome of subjects consuming 
alcohol (HDC, MAH and SAH all combined) was significantly enriched with the obligate 
anaerobic non-spore forming Gram-negative bacilli phylum Fusobacteria and its 
subclasses Fusobacteriales and Leptotrichiaceae (Fig. 2a). Interestingly, the degree of 
enrichment was greatest in HDC followed by MAH and then SAH (data not shown). 
Other gram negative bacteria that were enriched in the alcohol-consuming groups (vs. 
NACs) included Neisseriaceae, Chitinophagaceae, Bradyrhizobiaceae, and 
Peptostreptococcaceae (Fig. 2a). Alcohol consuming groups were also enriched in 
gram positive taxa predominantly those under phyla Actinobacteria (genus Turicella and 
Microbacterium) and Firmicutes (genus Anaerococcus, Lachnospiraceae incertae sedis, 
and Clostridium XI) (Fig. 2b).  
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In addition, gender based comparison of circulating microbiota was also  
performed. In NAC group, Lachnospiraceae was enriched in males while in alcohol  
group (HDC, MAH and SAH) females were enriched in genus Actinomyces of phylum  
Actinobacteria and order Sphingomonadales and family Sphingomonadaceae belonging  
to the phylum Proteobacteria (supplementary figure 2A and 2B).   
  
Alcohol consumption and presence of AH affect bacterial composition within specific  
phyla  
 The complex overlay of the differences in distribution of the microbiome across  
the study groups were next visualized using Venn diagrams (Fig. 3a). Overall NACs  
were enriched with 77 taxa compared to those consuming alcohol (Fig. 3a, panel 1, bar  
plot), but only 9 taxa had common enrichment when compared to all groups consuming  
alcohol (Fig. 3a, panel 1, Venn diagram). Conversely, the alcohol consuming groups  
were enriched in 43 taxa compared to the NACs (Fig. 3a, panel 2, bar plot) but only 4  
common taxa were enriched in alcohol groups (Fig. 3a, panel 2, Venn diagram).  
The differential enrichment of specific bacteria at a family and genus level  
compared to NAC is shown in cladograms (Fig. 3b) and histograms respectively (Fig.  
3c) based on a LDA score > 2 for pairwise comparisons. Certain families were enriched  
in more than one alcohol group: Peptostreptococcaceae (HDC, MAH and SAH),  
Leptotrichiaceae (HDC and SAH), Bradyrhizobiaceae (HDC, MAH and SAH), and  
Neisseriaceae (HDC and SAH). Specific enrichment for individual alcohol groups  
compared to NAC included Streptomycetaceae (HDC), Carnobacteriaceae and  
Page 14 of 57
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 15 
 
Clostridiales Incertae Sedis XI (MAH); and Corynebacteriaceae, Dermabacteraceae,  
and Micromonosporaceae (SAH).   
Within the Actinobacteria phylum, Nocardioides was uniformly enriched in the  
NAC compared to all other alcohol groups (Fig. 3C). Specifically enriched genus for  
different alcohol groups vs. NAC group included Kocuria and Streptomyces (for HDC),  
Actinomyces (for MAH) and Corynebacterium and Brachybacterium (for SAH).    
Within the phylum Bacteroidetes, the NAC group was uniformly enriched in  
genus Prevotella and Flavobacterium when compared to all other alcohol groups (Fig.  
3c). Also, order Bacteroidales and families Porphyromonadaceae and Prevotellaceae  
were enriched in NAC vs. all other alcohol groups. In contrast, compared to the NAC,  
each of the alcohol study groups was specifically enriched in a particular genus:  
Chryseobacterium (HDC), Cloacibacterium (MAH) and Gillisia (SAH).   
 For the phylum Firmicutes, subjects within the NAC group were enriched in  
Clostridium sensustricto compared to all alcohol consuming groups. The genus  
Anaerococcus and Clostridium XI were also enriched in all alcohol-consuming groups  
compared to the NAC. Within the phylum Fusobacteria, both HDC and SAH groups  
were enriched in Leptotrichiaceae family whereas only the SAH group was enriched  
with Leptotricha.   
 Within the phylum Proteobacteria (Fig. 3c), Acinetobacter (OTU0021) was  
enriched in NAC vs. all alcohol groups while the genus Bradyrhizobium and  
Acinetobacter (OTU0019) were enriched in all alcohol groups vs. the NAC. On pairwise  
comparison, genus Phenylobacterium, Rhodobacter, and Neisseria were all enriched in  
HDC vs. NAC (Fig. 3c). Also, both MAH and SAH were enriched with genus  
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Methylobacterium and Curvibacter. Notably SAH subjects compared to NAC were 
specifically enriched with genus Burkholderia and Cupriavidus.    
Distinct Circulating Microbiome Enrichment in Alcoholic Hepatitis (Fig. 4a and 4b): 
There were specific changes in the microbiome in those with AH compared to 
NAC.  While moderate AH was associated with enrichment of Coriobacteriaceae and 
Streptococcaceae, severe AH was associated with enrichment of Dermabacteraceae 
and Micromonosporaceae (Fig. 4a).  As shown in the LDA > 2 histograms with pairwise 
comparisons, both AH groups were enriched with the genus Turicella and Curvibacter. 
Moderate AH and severe AH were also associated with specific enrichment of several 
genus compared to the NAC (Fig. 4b). Conversely, NAC showed specific enrichment of 
genus Microbacterium (vs. MAH), and Rhodococcus, Hymenobacter, Roseomonas and 
Janthinobacterium (vs. SAH) (Fig. 4b). 
 
Circulating measures of endotoxemia and monocyte activation in Alcoholic Hepatitis: 
Plasma LPS levels (EU/ml) were significantly increased in SAH compared to 
HDC (mean ± S.D., HDC 0.039 ± 0.007 vs. MAH 0.048 ± 0.01 vs. SAH 0.051 ± 0.01, 
p=0.01 HDC vs. SAH, Supplementary Fig. 1). However, no significant differences were 
seen in plasma LBP levels (µg/ml) among the alcohol consuming groups regardless of 
the presence and severity of AH (HDC 12.2 ± 6.8 vs. MAH 11.3 ± 5.5 vs. SAH 11.5 ± 
9.1). Also, no significant correlation between circulating 16S and LPS was observed 
(r2=0.006, p=0.58). Soluble CD14 (sCD14) levels (µg/ml) were higher and statistically 
significant (overall p=0.01) in subjects with MAH vs. HDC (2.6 ± 0.8 vs. 1.9 ± 0.5, 
p=0.03) as well as vs. SAH (1.9 ± 0.8, p=0.04).  
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Interrelationships of disease severity, monocyte activation, endotoxemia and circulating  
microbiome:   
Gram negative Proteobacteria and Gram positive Firmicutes were inversely  
related in non-drinking controls (ρ= -0.5, p=0.02).  This relationship became more  
distinct in HDC (ρ= -0.84, p<0.0001), and most notable in SAH (ρ= -0.95, p<0.0001).   
Bacterial class Gammaproteobacteria and Betaproteobacteria were inversely  
correlated to MELD, Maddrey’s DF and CTP scores (ρ= -0.47 to -0.67, p< 0.05 for all).  
Moreover, on regression analysis the relative abundances of genus Janthinobacterium  
(p=0.02, r= -0.30) was inversely related to the MELD score (Fig. 5). Similarly,  
Enhydrobacter was also inversely related to the MELD score (p=0.03, r= -0.29).  
However, neither LBP nor LPS were significantly correlated with either with disease  
severity scores (MELD, CTP and DF) or stage of disease (HDC, MAH and SAH),  
suggesting that heavy alcohol use with and without AH potentially produced comparable  
endotoxemia.  
The sCD14 levels were inversely correlated with MELD score (ρ= -0.73 in MAH,  
p=0.0005; ρ= -0.47 in SAH, p=0.04) and DF (ρ= -0.76 in MAH, p=0.003). While sCD14  
was inversely correlated with Actinomycetales in HDC and Coriobacteriales in SAH,  
plasma LBP was inversely correlated with Rhodobacterales in HDC and  
Xanthomonadales in SAH (ρ= -0.5 to -0.63, p< 0.05 for all).    
  
Impact of antibiotic use on circulating microbiome:  
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A total of 6/19, 10/18 and 14/19 subjects in the HDC, MAH and SAH groups were 
on systemic antibiotics (p=0.03 for trend) at the time of sample collection even though 
there was no documented infection in these subjects at the time of sample collection. 
None of the NAC subjects had any recent (within 1 month) antibiotic use.  Regardless of 
the group and the specific antibiotic used, those on antibiotics had an enrichment in 
Bacteroides-Bacteroideaceae while those without antibiotic exposure had an 
enrichment in Hymenobacter and Janthinobacterium.  Importantly, the key findings 
distinguishing the changes in the circulating microbiome across groups presented 
above were not altered by antibiotic exposure with the exception of Janthinobacterium 
in the alcoholic hepatitis groups where it was inversely related to MELD scores. Further, 
subjects with alcohol use and no antibiotic exposure (both HDC and AH, as well as all 
alcohol groups combined) were compared to NAC group. The principal findings in 
circulating microbiota composition were similar to the original overall cohort (subjects 
with and without antibiotic exposure, supplementary figure 3A and 3B). 
 
Functional Circulating Metagenome in Alcoholics and Severe Alcoholic Hepatitis:  
Inferred metagenomics analysis using PICRUSt was performed to predict the 
functional potential of the circulating metagenome in relation to the alcohol consumption 
and presence of AH. First, the NAC group when compared to heavy alcoholics (HDC, 
MAH and SAH) had markedly enriched metabolic pathways containing gene functions 
such as methanogenesis, denitrification, citrate cycle, glucuronate/uronate and 
glycosaminoglycan metabolism including keratan sulfate degradation (Fig. 6a). In 
contrast, heavy alcoholics (HDC, MAH and SAH) compared with NAC, were enriched 
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for genes of structural components of the Type III secretion system (T3SS) (Fig. 6b).  
Similarly, functional metagenomics predicted lysine, arginine, ornithine, methionine and  
histidine transport systems were activated in heavy alcoholics (HDC, MAH and SAH,  
Fig. 6b).   
Next we compared SAH vs. NAC groups. Interestingly, SAH subjects had  
markedly enhanced isoprenoid biosynthesis via mevalonate pathway compared to non- 
mevalonate pathway in NAC (Fig. 7a). Also, in SAH other notable metabolic pathways  
that were predictably enhanced included anthranilate degradation pathway, which is  
associated with bacterial biofilm formation, and ketone body biosynthesis among others  
(Fig. 7a). Furthermore, the SAH group was enriched with bacterial community  
associated with hemophore metalloprotease, vitamin B12, phosphonate transport  
systems and T3SS, among other amino acid transport systems (Fig. 7b).    
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DISCUSSION   
There is growing appreciation that the human body represents a complex eco- 
system where the host lives in a symbiotic relationship with resident microbiota.   
Perturbations in the microbiome are associated with multiple disease states. While  
numerous studies have documented such changes in the intestinal microbiome in those  
with an alcohol use related liver disease, the changes in the circulating microbiome  
were not previously known.  The current study indicates that there are indeed multiple  
changes in the circulating microbiome both in heavy alcohol consumers without overt  
liver disease and with alcoholic hepatitis. More importantly, these changes are  
associated with shift in the metabolic functions of the circulating microbiome.   
A key finding from this study is the decrease in the blood-borne signature of  
relative abundance of the phylum Bacteroidetes in all groups consuming alcohol  
compared to non-drinking controls.  Previously, a variable increase in fecal  
Bacteroidetes was reported in relation to alcohol use disorders and a more consistent  
increase was noted in nonalcoholic fatty liver disease (28-30). Of note, the previously  
reported increase in Proteobacteria in those with heavy alcohol consumption (fecal and  
mucosal) and subjects with NAFLD (18, 31, 32) was not observed in the circulating  
microbiome in alcohol-consuming subjects in this study. The relationship and cross-talk  
between the fecal microbiome and the circulating microbiome is a yet largely  
unexplored area of research and modulation of circulating microbial signatures are likely  
to be multifactorial in origin. These could include changes in diet, intestinal microbiota,  
altered gut barrier function and gut-based immune responses.  The current data set the  
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stage for hypothesis-generation and future mechanistic studies in the context of 
alcoholic hepatitis. 
Previous studies have noted an increase in Fusobacteria in feces of individuals 
with cirrhosis including alcohol-induced cirrhosis(33). Furthermore, an enrichment with 
Fusobacteria was noted in those with overt hepatic encephalopathy (34). This had led to 
the concept that they may directly influence the development of this cirrhosis-related 
complication.  The current data extend the observation of increased Fusobacteria in 
stool of those with cirrhosis to the circulation.  A novel observation is that it is enriched 
in even the heavy drinking controls and that the development and severity of AH was 
inversely related to the degree of enrichment with Fusobacteria. One may thus 
hypothesize that this inverse relationship may reflect the protective value of increased 
Fusobacteria in those who consume large amounts of alcohol and that the failure to 
increase these bacteria allow the liver disease to develop and increase in severity. This 
remains hypothetical and needs to be validated in appropriately designed studies.   
A key challenge in evaluating the potential role of the circulating microbiome in 
health and disease is that specific bacteria can’t be removed or added to circulation to 
see their impact on specific physiological processes. Furthermore, the circulating 
microbiome signature is present in healthy hosts and does not represent an immune 
deficiency or infection in the traditional sense.  The mechanisms by which they establish 
a symbiotic relationship with the host immune system also remains largely unknown.  
The development of specific methodology to evaluate gain or loss of function of the 
microbiota is now a major unmet need to fully leverage the observed changes in the 
circulating microbiome to improve human health. 
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Until such methods are developed, analytic tools such as inferred metagenomics 
can be used to assess the potential impact of changes in bacterial relative abundance 
on the functionality of the microbiome. In this study, such analyses indicated that the 
circulating microbiome of non-drinking controls were enriched with respect to 
methanogenesis, de-nitrification and several other functions.  A growing body of 
literature indicates an important role of gases as “signaling” molecules and both 
methane and hydrogen sulfide have been implicated as regulators of intestinal epithelial 
integrity and gut-derived inflammatory signals (35, 36). A likely possibility is that 
circulating bacteria, by producing even minute quantities of such gases, and/or 
pathogen-associated molecular patterns (PAMPs) may modulate signaling within the 
innate and adaptive immune system, modify oxidative stress, and affect the 
microcirculation and even cellular function in individual organs.  This possibility is further 
supported by the well-established roles of nitric oxide and carbon monoxide as 
modulators of endothelial dysfunction, microcirculation, organ function and inflammation 
particularly in the liver (37-40).   
Another noteworthy finding is that the functional metagenome shows enrichment 
of genes for structural components of the Type III secretion systems (T3SS) in HDC and 
SAH. This finding is highly relevant because the T3SS machinery is uniquely related to 
the pathogenicity of gram-negative bacteria. The T3SS apparatus consists of a needle-
like injectisome complex (41) that promotes virulence by translocating effector proteins 
into host cells where they exert anti-host effects such as facilitated invasion, intracellular 
survival, phagocytic avoidance, and disruption of host defenses (42). This could explain 
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one of the mechanisms of increased risk of Gram negative pathogens in patients with  
heavy alcohol use and severe alcoholic hepatitis.  
Also noteworthy is isoprenoid biosynthesis pathway on functional metagenome.  
Isoprenoids are vital for the growth and survival of prokaryotes, supporting core  
functions such as cell wall and membrane synthesis, and aerobic respiration among  
others (43). Enhanced isoprenoid biosynthesis via the mevalonate pathway, mainly  
seen in Gram positive pathogens (44) may contribute to the risk of Gram positive  
pathogen infection in SAH. In fact, Gram positive Enterococcus emerged as the most  
frequent cause of infection in SAH patients (45).   
Notably, in patients with SAH there is shift in function of circulating microbiota  
with enrichment of the anthranilate degradation pathway. This pathway is significant in  
forming bacterial biofilm as previously shown (46). Bacterial biofilm also contributes to  
the pathogenesis, and antibiotic/host immune resistance to a number of medically  
important bacterial strains (47) and likely plays an important role in infections associated  
in patients with SAH. Together, these findings on functional aspects of circulating  
microbiome provide direction for future research and could potentially lead to the  
development of novel therapeutic approaches.  
Heavy alcohol consumption has been linked to endotoxemia (48) and endotoxin  
load is widely believed to represent a key pathophysiological step in the genesis of  
alcoholic hepatitis. The current data also support a role for factors beyond endotoxemia  
in the genesis of alcoholic hepatitis and thus extend the existing paradigm. It is also  
interesting to note the inverse relationship between sCD14, a marker of monocyte  
activation through TLR4, and the severity of alcoholic hepatitis.  Theoretically, this could  
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be due to immunosuppression associated with SAH; the current data provide the  
rationale for testing this hypothesis in the future.  
The current study does have some limitations that need to be considered in  
evaluating the data. The control groups did not have a liver biopsy for logistical and  
ethical considerations and so the possibility of clinically unapparent disease can’t be  
completely excluded.  This possibility was however minimized by selecting  
asymptomatic individuals with normal liver enzymes and hepatic function. The diagnosis  
of alcoholic hepatitis was also based on clinical criteria without mandatory requirement  
of liver biopsy and one could question if some of these individuals had alternate  
diagnoses as has been suggested by others (49, 50).  We believe that the probability of  
not having alcoholic hepatitis in our subjects is low because sepsis leading to  
decompensated cirrhosis, a key diagnostic confounder, was carefully excluded in all  
cases. Furthermore, alternate causes of liver disease such as viral hepatitis, etc., were  
excluded in all individuals.  It is however possible and indeed probable that many of the  
subjects had alcoholic hepatitis superimposed on cirrhosis as has been observed  
previously.  While the use of antibiotics alter the circulating microbiome, they did not  
impact the principal differences between the study groups.  Therefore the findings  
reflect the changes in those with alcoholic hepatitis in a “real world” setting which  
usually include alcoholic hepatitis superimposed on cirrhosis rather than pure alcoholic  
hepatitis. Also, effects of diet, previous antibiotics exposure and correlation with  
concomitant gut microbiome could not be derived due of lack of these data in the  
present study, and their relationship merits further exploration by specifically designed  
studies in the future. Also, we used MELD score of >20 to define SAH, which has less  
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variability than discriminant function (DF) as previously published (6). Thus, there is a  
small potential for obtaining somewhat different data if the thresholds to separate MAH  
vs. SAH were based on the DF.   
Much work remains to be done to better understand the physiological and  
pathophysiological functions of the circulating microbiome.  The current study provides  
the first description of the compositional changes associated with alcoholic hepatitis and  
shift in the metabolic functions of circulating microbiota. These provide the foundational  
basis for future focused studies on the role of the circulating microbiome and its related  
metabolites in the genesis of alcohol associated liver disease.   
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TABLES:  
Table 1: Characteristics of the study cohort 
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FIGURE LEGENDS: 
 
Fig 1: Whole blood sample 16S rDNA sequence, diversity analysis and relative 
taxonomic abundances.  
 
Fig. 1A: A scatter plot depicting 16S copies/ngDNA among the study groups. There is a 
step wise increase in 16S copies/ngDNA from NAC to HDC to MAH to SAH. Compared 
to NAC group, both MAH and SAH showed significantly higher 16S copies/ngDNA using 
Kruskal Wallis test. 
 
Fig. 1B: Stacked column bar graphs depicting the individual sample phylum level 
taxonomic abundance by study group for 16S targeted sequence analysis. Taxa were 
identified by name for the most abundant phyla or merged into the “Other” category for 
below 0.5% abundance. 
 
Fig. 1C: Plots of microbiome alpha diversity (Shannon index), representing the mean of 
species diversity per sample at the genus level with respect to alcohol use study 
groups, demonstrating a small but insignificant shift toward lower diversity in alcohol 
using subjects and corresponding to disease severity. 
 
Fig. 1D: Principal Component Analysis (PCoA) unsupervised dimensional reduction 
plots depicting the relationships between the microbiomes with respect to alcohol use 
study groups based on weighted UniFrac methodology for β-diversity. 
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Fig. 1E: On Partial Least Square Discriminant Analysis the study groups are separated 
by supervised dimensionality reduction multivariate regression model. 
 
Fig. 1F: Stacked column bar graphs depicting the average phylum level taxonomic 
abundance by study group for 16S targeted sequence analysis. Taxa were identified by 
name for the most abundant phyla or merged into the “Other” category for below 0.5% 
abundance. Significantly lower relative abundance of the phylum Bacteroidetes was 
seen in the alcoholic (HDC, MAH, SAH) vs. the nonalcoholic controls (NAC) using 
Kruskal Wallis test. 
NAC = Non Alcoholic Controls, HDC = Heavy Drinking Controls, MAH = Moderate 
Alcoholic Hepatitis, SAH = Severe Alcoholic Hepatitis 
 
Fig. 2: Differential group taxonomic features relative to use of alcohol.  
Fig. 2A: LDA Effect Size (LEfSe) cladograms of pairwise analysis for nonalcoholic 
controls (NAC) and combined alcoholic groups (HDC + MAH + SAH) for 16S rDNA 
sequence analysis of whole blood samples. The cladogram shows the taxonomic levels 
represented by rings with phyla at the innermost ring and genera at the outermost ring, 
and each circle is a member within that level. Taxa at each level are shaded green 
(NAC) or orange (Alcoholics) in which it is more abundant (P < 0.05; LDA score >2.0). 
The LEfSe analysis indicates differential signatures based on alcohol use by subjects.  
 
Fig. 2B (Table): LDA effect size plots of pairwise analysis for the nonalcoholic controls 
(NAC) and combined alcoholic groups (HDC + MAH + SAH) for 16S rDNA sequence 
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analysis of whole blood samples. The phylum and subsequent taxonomic levels are 
sorted alphabetically and the corresponding LDA score indicated in the furthest right 
column according to the group in which it is more abundant (P < 0.05; LDA score >2.0). 
 
Fig. 3: Differential group taxonomic features relative to nonalcoholic control study 
group.  
Fig. 3A: Venn diagrams indicating the number of common differential features 
(KW<0.05, LDA>2.0) from any taxonomic level (phylum to genus) that are enriched in 
the nonalcoholic group (NAC, left panel Venn) or enriched in the alcoholic groups (HDC 
+ MAH + SAH, right panel Venn). 
 
Fig. 3B: LDA Effect Size (LEfSe) cladograms of pairwise analysis for the nonalcoholic 
controls (NAC) and each individual alcoholic group (HDC, MAH, or SAH) for 16S rDNA 
sequence analysis of whole blood samples. The cladogram shows the taxonomic levels 
represented by rings with phyla at the innermost ring and genera at the outermost ring, 
and each circle is a member within that level. Taxa at each level are shaded green 
(NAC), blue (HDC), violet (MAH), or red (SAH) according to the alcohol use group in 
which it is more abundant (P < 0.05; LDA score >2.0).  
 
Fig. 3C (Table): LDA effect size plots of pairwise analysis with nonalcoholic controls 
(NAC) and each individual alcoholic group (HDC, MAH, or SAH) for 16S rDNA 
sequence analysis of whole blood samples. The phylum and subsequent taxonomic 
levels are sorted alphabetically and the corresponding LDA scores for each pairwise 
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analysis with the NAC group are indicated in columns to the right according to the group 
in which it is more abundant (P < 0.05; LDA score >2.0). The furthest right column 
indicates the nine common taxonomic features enriched in the NAC group and the four 
common taxonomic features enriched in the alcoholic groups. 
 
Fig. 4: Distinct Circulating Microbiome Enrichment in Alcoholic Hepatitis 
Fig. 4A: LDA Effect Size (LEfSe) cladograms of pairwise analysis for each alcoholic 
group (HDC, MAH, and SAH) for 16S rDNA sequence analysis of whole blood samples. 
The cladogram shows the taxonomic levels represented by rings with phyla at the 
innermost ring and genera at the outermost ring, and each circle is a member within that 
level. Taxa at each level are shaded blue (HDC), violet (MAH), or red (SAH) according 
to the alcohol use group in which it is more abundant (P < 0.05; LDA score >2.0).  
Fig. 4B (Table): LDA effect size plots of pairwise analysis for each alcoholic group 
(HDC, MAH, and SAH) for 16S rDNA sequence analysis of whole blood samples. The 
phylum and subsequent taxonomic levels are sorted alphabetically and the 
corresponding LDA scores for each pairwise analysis are indicated in columns to the 
right according to the group in which it is more abundant (P < 0.05; LDA score >2.0).  
 
Fig 5: Disease severity MELD regression plots.  
Regression analysis plots of 16S rDNA sequence relative abundance relative to MELD 
disease score. Two genera, Janthinobacterium and Enhydrobacter, from the phylum 
Proteobacteria were identified to have a negative correlation with MELD disease score. 
HDC (blue), MAH (purple) and SAH (red). 
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Fig 6: Predicted metagenome metabolic pathway and structural complex analysis. 
LDA Effect Size (LEfSe) cladograms of pairwise analysis for the nonalcoholic controls 
(NAC) and combined alcoholic groups (HDC + MAH + SAH). The cladograms show the 
KEGG hierarchy for A) metabolic pathways and B) structural complexes represented by 
rings with the pathway or structural modules at the outermost ring, and each circle is a 
member within that level. KEGG modules are shaded green (NAC) or orange 
(alcoholics) according to the study group in which it is more abundant (P < 0.05; LDA 
score >2.0).  
 
Fig 7: Predicted metagenome metabolic pathway and structural complex analysis. 
LDA Effect Size (LEfSe) cladograms of pairwise analysis for the nonalcoholic controls 
(NAC) and severe alcoholic hepatitis (SAH). The cladograms show the KEGG hierarchy 
for A) metabolic pathways and B) structural complexes represented by rings with the 
pathway or structural modules at the outermost ring, and each circle is a member within 
that level. KEGG modules are shaded green (NAC) or red (SAH) according to the study 
group in which it is more abundant (P < 0.05; LDA score >2.0). C) An overview of 
changes in the metabolic function and structural complex in HDC and SAH compared to 
NAC. 
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